DV
Dividend Vision

ANTX — AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX)

Total return is -61.1% over the past 4.4 years, 142.8 points behind SPY at 81.7%. Its deepest 1-year drawdown was 45.6%.

AN2 Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics, with its lead candidate epetraborole in phase 3 clinical trials for non-tuberculous mycobacterial lung disease and acute melioidosis, and a pipeline including programs in chronic Chagas disease, oncology, and infectious disease based on its boron chemistry platform. The company does not currently distribute dividends. AN2 Therapeutics appeals primarily to investors seeking exposure to clinical-stage biotech companies with focus on infectious disease and rare disease treatments.

ANTX key facts

Asset type
Stock
Asset class
Equity
Inception date
03/25/2022
Last close
$5.99
Market cap
$168,555,616
Average volume
198352.0
Beta
-0.987
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.10